Using ‘omic and digital technologies toward better fasciolosis control

使用组学和数字技术更好地控制片形吸虫病

• 批准号: FT230100559
• 负责人: A/Prof Neil Young
• 金额: $ 65.43万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2023
• 资助国家: 澳大利亚
• 起止时间: 2023-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT230100559
• 关键词: Using; omic; digital; technologies; toward

In Australia, liver fluke disease caused by Fasciola hepatica causes major economic losses to livestock production. Triclabendazole is the most effective drug for parasite control, however, resistance to this drug has emerged and continues to spread in Australia. This project expects to create a novel resource to identify new drug targets, generate new knowledge about the genetic composition of F. hepatica populations and unravel the genetic determinants underlying triclabendazole resistance. The curation of functionally-annotated genetic data for F. hepatica populations will underpin the development of diagnostic tests, drugs and vaccines to deliver a new generation of intervention strategies to control liver fluke disease.

在澳大利亚，由肝片形吸虫引起的肝吸虫病给畜牧业生产造成重大经济损失。三氯苯达唑是控制寄生虫最有效的药物，然而，对这种药物的耐药性已经出现，并继续在澳大利亚蔓延。该项目有望创造一种新的资源，以确定新的药物靶点，产生关于F. hepatica种群和解开潜在的三氯苯达唑耐药的遗传决定因素。功能注释的F。肝吸虫种群将支持诊断测试、药物和疫苗的开发，以提供新一代控制肝吸虫病的干预战略。